UNSPSC 51373400: Combination opioid-containing antitussives and expectorants

This classification denotes combination drugs and preparations that do bind to opioid receptors, which do derive from opium or morphine, which are addictive, and which are narcotics, that a) suppress cough, hence the term ANTITUSSIVES; and/or b) increase mucous excretion, hence the term EXPECTORANTS. These drugs therefore bear the names OPIOID-CONTAINING ANTITUSSIVES AND EXPECTORANTS. Typical combination opioid-containing antitussive and expectorant constituents are codeine, dihydrocodeine, hydrocodone, morphine, etc.

UNSPSC 51373400 Combination opioid-containing antitussives and expectorants is a Class code that in recent state and local procurement activity covers the supply of naloxone, drug deactivation systems, and generic multi-source pharmaceuticals and over-the-counter products to health departments, community health facilities, and participating state and local government agencies. The code shows limited alignment between its nominal scope (opioid-containing cough medicines) and the actual work being solicited: recent opportunities tag naloxone procurement and broad generic pharmaceutical supply agreements under this code, neither of which matches the code's stated pharmaceutical class. State and local issuing bodies using the code include county health departments, state departments of administration managing cooperative purchasing, and participating municipalities within multistate purchasing alliances; the Minnesota Department of Administration's Office of State Procurement and Seminole County, Florida appear as recent users.

Activity is concentrated in Florida and Minnesota, with the MMCAP cooperative purchasing vehicle extending participation to Oregon and other member states. Representative recent opportunities include Seminole County's IFB 60459723LAS (posted June 30, 2026, due July 26, 2026 originally stated as 2023 in the source) for 1,900 units of naloxone and 800 drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building, and the Minnesota Department of Administration's MMCAP RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) to establish multi-award generic pharmaceutical and OTC contracts through three authorized wholesalers with effective date July 1, 2026. The MMCAP solicitation requires vendors to comply with cGMP and Drug Supply Chain Security Act (DSCSA) standards, maintain relationships with at least two of three wholesalers, and accept a 3 percent administrative fee, with evaluation weighted 75 percent on price competitiveness and 25 percent across fixed pricing, administrative data compliance, EDI capability, and fee acceptance. Neither recent opportunity discloses specific budget ranges or set-aside designations for disadvantaged enterprises.